top of page
dna-7090994.jpg

Eliminating solid tumors with AI-driven, multiplex gene-edited CAR-T cells

Advancing cell therapies that break through immunosuppressive tumor barriers, enabling effective and durable cancer control  

About

Our Support

2048 Ventures Biotech Studio Program
KiraGen Bio is proud to join the 2048 Ventures Biotech Studio, marking a pivotal step in our quest to innovate CAR-T therapies for solid tumors. This recognition fuels our journey with vital resources and expert networks, accelerating our path to transforming cancer treatment.
BioLM_edited_edited_edited.jpg
Our collaboration with BioLM propels the development of our state-of-the-art KiraLOGIC® Machine Learning model with the latest in AI technology. This partnership will accelerate the rational design of our TME-Guarded CAR-T cell therapies, showcasing our commitment to pioneering innovative cancer treatment solutions.

Recognitions

Harvard Undergraduate Capital Partners Innovation
Harvard Consulting Business and the Environment

HUCP Innovation Fund x CBE Ventures Competition

Finalists in the 2023 Harvard Undergraduate Capital Partners Innovation Fund x Consulting, Business, the Environment Venture Competition

KiraGen Bio Logo

Nucleate Activator Program

Finalists in the 2024 Nucleate Activator Program final pitch showcase in Boston

President's Innovation Challenge

Presidents Innovation Challenge

Semi-finalists in the 2024 Harvard iLab's President's Innovation Challenge

Science

Redefining CAR-T with a differentiated approach:

AI-driven design and multiplex gene editing for superior efficacy against solid tumors.

Our Science

KiraLOGIC

AI-Driven Design

Leveraging machine learning to pinpoint optimal gene editing combinations, enhancing CAR-T cell efficacy against solid tumors.

DNA icon_edited_edited_edited.png

Multiplex Gene Editing

Employing cutting-edge technology to simultaneously edit 8+ genes, setting a new standard in cell therapy engineering.

KGEN-101 Allogeneic CAR-T Cells

Allogeneic CAR-T

Our allogeneic CAR-T cells are engineered to maintain efficacy against immunosuppressive solid tumor microenvironment.

Team

Meet the Team

Aaron Edwards experience
Ryan Murray experience
Life Lab Pic.jpeg
bottom of page